Lake Street analyst Ryan Meyers lowered the firm’s price target on Joint Corp. (JYNT) to $16 from $20 and keeps a Buy rating on the shares. The firm believes The Joint continues to make positive strides in its corporate clinic transition following its first quarter 2025 results, but is trimming its price target based on a lower 2026 EBITDA estimate.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JYNT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue